Download PDF
Pharmacopsychiatry 2002; 35(3): 112-115
DOI: 10.1055/s-2002-31515
Case Report
© Georg Thieme Verlag Stuttgart · New York

Paroxetine Associated Hepatotoxicity: A Report of 3 Cases and a Review of the Literature

T.  Azaz-Livshits, A.  Hershko, E.  Ben-Chetrit
  • 1Department of Medicine and Clinical Pharmacology, Hadassah University Hospital, Jerusalem, Israel
Further Information

Publication History

24. 1. 2001

15. 6. 2001

Publication Date:
23 May 2002 (online)

Also available at
    Permissions and Reprints

We recently encountered 3 patients who had developed reversible paroxetine-associated hepatotoxicity. Two of the patients were over 80 years old and their hepatitis was accompanied by hyponatremia. In the third case, hepatitis was associated with multiple organ failure and the co-administration of trazodone. Here, we will discuss the possible role of preexisting risk factors in the development of paroxetine hepatotoxicity and review the relevant literature.

References

  • 1 Beck P L, Bridges R J, Demetrick  D J. et al . Chronic active hepatitis associated with trazodone therapy.  Ann Intern Med. 1993;  118 10-16
    PubMedGoogle Scholar
  • 2 Benbow S J, Gill G. Paroxetine and hepatotoxicity.  BMJ. 1997;  314 s1387
    PubMedGoogle Scholar
  • 3 Boyer W F, Blumhardt C L. The safety profile of paroxetine.  J Clin Psychiatry. 1992;  53 (6) 61-66
    PubMedGoogle Scholar
  • 4 Brogden R N, Heel R C. et al . Trazodone: review pharmacological properties and therapeutic use in depression and anxiety Drugs.  . 1981;  21 401-429
    PubMedGoogle Scholar
  • 5 Brondeau M T, Ban M, Bonnet P, Guenier J, De Ceaurriz J. Concentration-related changes in blood and tissue parameters of hepatotoxicity and their interdependence in rats exposed to bromobenzene and 1,2-dichlorobenzene.  Toxicol Lett. 1986;  31 (2) 159-166
    CrossrefPubMedGoogle Scholar
  • 6 Cadranel J F, Martino V, Cozier A. et al . Atrium and paroxetine-related severe hepatitis.  J Clin Gastroenterol. 1999;  28 52-55
    CrossrefPubMedGoogle Scholar
  • 7 Chu A G, Gansolly B L, Summers R W. et al . Chronic active hepatitis associated with trazodone therapy.  Ann Intern Med. 1983;  99 128-129
    PubMedGoogle Scholar
  • 8 Doyle G D, Laher M, Kelly J G. et al . The pharmacokinetics of paroxetine in renal impairment.  Acta Psychiatr Scand. 1989;  80 (350) 89-90
    PubMedGoogle Scholar
  • 9 Dunbar G C, Claghorn J L, Kiev A. et al . A comparison of paroxetine and placebo in depressed patients.  Acta Psychiatr Scand. 1993;  87 302-305
    PubMedGoogle Scholar
  • 10 Fenichel R R. Drug-induced hepatotoxicity.  N Engl J Med. 1996;  334 (13) 864
    CrossrefPubMedGoogle Scholar
  • 11 Helmchen C, Boerner R J, Meyendorf R. et al . Reversible Hepatotoxicity of paroxetine in a patient with major depression.  Pharmacopsychiatry. 1996;  29 223-226
    PubMedGoogle Scholar
  • 12 Hiemke C, Hartler S. Pharmacokinetics of selective serotonin reuptake inhibitors.  Pharmacol Ther. 2000;  85 (1) 11-28
    CrossrefPubMedGoogle Scholar
  • 13 Horsmans Y, Lannes D, Pessayre D, Larrey D. Possible association between poor metabolism of mephenytoin and hepatotoxicity caused by Atrium, a fixed combination preparation containing phenobarbital, febarbamate and difebarbamate.  J Hepatol. 1994;  21 (6) 1075-1079
    CrossrefPubMedGoogle Scholar
  • 14 Kaye C M, Haddock R E, Langley P F. et al . A review of the metabolism and pharmacokinetics of paroxetine in man.  Acta Psychiatr Scand. 1989;  80 (350) 60-75
    PubMedGoogle Scholar
  • 15 Kuhs H, Rudolf G AE. A double-blind study of the comparative antidepressant effect of paroxetine and amitriptyline.  Acta Psychiatr Scand. 1989;  80 (350) 89-90
    PubMedGoogle Scholar
  • 16 Larrey D, Pageaux G P. Genetic predisposition to drug-induced hepatotoxicity.  J Hepatol. 1997;  26 (2) 12-21
    CrossrefPubMedGoogle Scholar
  • 17 Longstreth G F, Hershman J. Trazodone-induced hepatotoxicity and leukonychia.  J Amer Acad Dermatol. 1985;  13 149-150
    PubMedGoogle Scholar
  • 18 Man R A. Severe hepatitis attributed to paroxetine. In Dutch.  Ner Tijdschr Geneeskd. 1997;  141 (11) 540-542
    PubMedGoogle Scholar
  • 19 Mann S C, Walker M M, Messenger G G, Greenstein R A. Leukocytoclastic vasculitis secondary to trazodone treatment.  J Am Acad Dermatol. 1984;  10 (4) 669-670
    PubMedGoogle Scholar
  • 20 Meynaar I A, Peelers A J, Mulder A H. et al . Syndrome of inappropriate ADH secretion attributed to the serotonin re-uptake inhibitors, venlafaxine and paroxetine.  Neth J Med. 1997;  50 243-245
    PubMedGoogle Scholar
  • 21 Rasmussen B B, Brossen K. Is therpeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors.  Ther Drug Monit. 2000;  22 (2) 143-154
    CrossrefPubMedGoogle Scholar
  • 22 Rickels K, Amsterdam J, Clary C. et al . A placebo-controlled, double blind clinical trial of paroxetine in depressed outpatients.  Acta Psychiatr Scand. 1989;  80 (350) 117-123
    PubMedGoogle Scholar
  • 23 Schatzberg A F. New indications for antidepressants.  J Clin Psychiatry. 2000;  61 (11) 9-17
    PubMedGoogle Scholar

Tanya Azaz-LivshitsPhD 

Dept. of Medicine

PO Box 12000

Jerusalem 91120

Israel

Email: azaz@hadassah.org.il

      >